Orbimed Advisors Llc Buys Regeneron Pharmaceuticals Inc, Amicus Therapeutics Inc, Loxo Oncology Inc, Sells Incyte Corp, Aetna Inc, Biogen Inc

• New Purchases: FOLD, RYTM, SCPH, DVA, ACAD, ASNS, AMED, ENDP, KIDS, SRPT,
• Added Positions: REGN, LOXO, NVRO, ASMB, DCPH, EVHC, RDUS, AMGN, VRNA, XNCR,
• Reduced Positions: AET, BIIB, MRK, GILD, ALXN, BSX, JNJ, ABBV, ARRY, A,
• Sold Out: INCY, MNK, SGYP, ONCE, DMTX, ICPT, NBIX, HCA, NLNK, TEVA,

For the details of ORBIMED ADVISORS LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=ORBIMED+ADVISORS+LLC

1. Biogen Inc (BIIB) - 1,230,700 shares, 4.99% of the total portfolio. Shares reduced by 24.5%
2. Alexion Pharmaceuticals Inc (ALXN) - 2,879,575 shares, 4.38% of the total portfolio. Shares reduced by 21.01%
3. Regeneron Pharmaceuticals Inc (REGN) - 854,600 shares, 4.09% of the total portfolio. Shares added by 49.20%
4. Celgene Corp (CELG) - 3,062,850 shares, 4.06% of the total portfolio. Shares reduced by 8.63%
5. Vertex Pharmaceuticals Inc (VRTX) - 1,741,300 shares, 3.32% of the total portfolio. Shares reduced by 16.05%

Orbimed Advisors Llc initiated holding in Amicus Therapeutics Inc. The purchase prices were between $12.51 and $16.24, with an estimated average price of $13.74. The stock is now traded at around $15.20. The impact to a portfolio due to this purchase was 1.02%. The holding were 5,572,500 shares as of 2017-12-31.

Orbimed Advisors Llc initiated holding in Rhythm Pharmaceuticals Inc. The purchase prices were between $22 and $30.51, with an estimated average price of $26.41. The stock is now traded at around $26.75. The impact to a portfolio due to this purchase was 0.55%. The holding were 2,901,295 shares as of 2017-12-31.

Orbimed Advisors Llc initiated holding in scPharmaceuticals Inc. The purchase prices were between $11.8 and $17.31, with an estimated average price of $14.03. The stock is now traded at around $16.25. The impact to a portfolio due to this purchase was 0.52%. The holding were 3,409,865 shares as of 2017-12-31.

Orbimed Advisors Llc initiated holding in DaVita Inc. The purchase prices were between $53.89 and $72.36, with an estimated average price of $61.55. The stock is now traded at around $70.01. The impact to a portfolio due to this purchase was 0.44%. The holding were 477,400 shares as of 2017-12-31.

Orbimed Advisors Llc initiated holding in ACADIA Pharmaceuticals Inc. The purchase prices were between $26.84 and $39.14, with an estimated average price of $32.01. The stock is now traded at around $24.99. The impact to a portfolio due to this purchase was 0.33%. The holding were 849,100 shares as of 2017-12-31.

Orbimed Advisors Llc initiated holding in Arsanis Inc. The purchase prices were between $10.87 and $18.48, with an estimated average price of $13.95. The stock is now traded at around $23.67. The impact to a portfolio due to this purchase was 0.3%. The holding were 1,868,966 shares as of 2017-12-31.

Orbimed Advisors Llc added to a holding in Regeneron Pharmaceuticals Inc by 49.20%. The purchase prices were between $358.63 and $469.95, with an estimated average price of $405.7. The stock is now traded at around $341.51. The impact to a portfolio due to this purchase was 1.35%. The holding were 854,600 shares as of 2017-12-31.

Orbimed Advisors Llc added to a holding in Loxo Oncology Inc by 5345.60%. The purchase prices were between $73.62 and $94.01, with an estimated average price of $83.48. The stock is now traded at around $131.57. The impact to a portfolio due to this purchase was 0.99%. The holding were 94,100,036 shares as of 2017-12-31.

Orbimed Advisors Llc added to a holding in Nevro Corp by 81.41%. The purchase prices were between $65.94 and $93.31, with an estimated average price of $80.08. The stock is now traded at around $87.10. The impact to a portfolio due to this purchase was 0.35%. The holding were 897,791 shares as of 2017-12-31.

Orbimed Advisors Llc added to a holding in Assembly Biosciences Inc by 60.16%. The purchase prices were between $28.58 and $48.15, with an estimated average price of $37.53. The stock is now traded at around $64.16. The impact to a portfolio due to this purchase was 0.26%. The holding were 1,198,026 shares as of 2017-12-31.

Orbimed Advisors Llc added to a holding in Deciphera Pharmaceuticals Inc by 198.29%. The purchase prices were between $16.54 and $24.2, with an estimated average price of $19.58. The stock is now traded at around $24.01. The impact to a portfolio due to this purchase was 0.23%. The holding were 1,176,070 shares as of 2017-12-31.

Orbimed Advisors Llc added to a holding in Envision Healthcare Corp by 98.64%. The purchase prices were between $24.79 and $45.13, with an estimated average price of $35.02. The stock is now traded at around $39.06. The impact to a portfolio due to this purchase was 0.19%. The holding were 875,400 shares as of 2017-12-31.

Orbimed Advisors Llc sold out a holding in Incyte Corp. The sale prices were between $93.56 and $116.6, with an estimated average price of $104.61.

Orbimed Advisors Llc sold out a holding in Mallinckrodt PLC. The sale prices were between $19.98 and $38.87, with an estimated average price of $26.89.

Orbimed Advisors Llc sold out a holding in Synergy Pharmaceuticals Inc. The sale prices were between $1.84 and $3.46, with an estimated average price of $2.49.

Orbimed Advisors Llc sold out a holding in Spark Therapeutics Inc. The sale prices were between $44.76 and $89.37, with an estimated average price of $72.05.

Orbimed Advisors Llc sold out a holding in Dimension Therapeutics Inc. The sale prices were between $5.9 and $6, with an estimated average price of $5.97.

Orbimed Advisors Llc sold out a holding in Intercept Pharmaceuticals Inc. The sale prices were between $58.2 and $72.76, with an estimated average price of $63.09.

Orbimed Advisors Llc reduced to a holding in Aetna Inc by 67.95%. The sale prices were between $151.44 and $182.73, with an estimated average price of $171.68. The stock is now traded at around $176.62. The impact to a portfolio due to this sale was -1.45%. Orbimed Advisors Llc still held 447,552 shares as of 2017-12-31.

Orbimed Advisors Llc reduced to a holding in Biogen Inc by 24.5%. The sale prices were between $307.64 and $344.58, with an estimated average price of $320.78. The stock is now traded at around $285.78. The impact to a portfolio due to this sale was -1.2%. Orbimed Advisors Llc still held 1,230,700 shares as of 2017-12-31.

Orbimed Advisors Llc reduced to a holding in Merck & Co Inc by 33.93%. The sale prices were between $54.1 and $64.6, with an estimated average price of $58.15. The stock is now traded at around $54.60. The impact to a portfolio due to this sale was -1.14%. Orbimed Advisors Llc still held 3,625,400 shares as of 2017-12-31.

Orbimed Advisors Llc reduced to a holding in Gilead Sciences Inc by 72.95%. The sale prices were between $71.15 and $83.52, with an estimated average price of $75.96. The stock is now traded at around $81.36. The impact to a portfolio due to this sale was -1.09%. Orbimed Advisors Llc still held 521,600 shares as of 2017-12-31.

Orbimed Advisors Llc reduced to a holding in Alexion Pharmaceuticals Inc by 21.01%. The sale prices were between $106.78 and $143.84, with an estimated average price of $121.98. The stock is now traded at around $122.19. The impact to a portfolio due to this sale was -1.03%. Orbimed Advisors Llc still held 2,879,575 shares as of 2017-12-31.

Orbimed Advisors Llc reduced to a holding in Boston Scientific Corp by 22.47%. The sale prices were between $24.79 and $29.8, with an estimated average price of $27.6. The stock is now traded at around $27.92. The impact to a portfolio due to this sale was -0.84%. Orbimed Advisors Llc still held 10,386,600 shares as of 2017-12-31.